Alzheimer ´s Disease in the Perspective of Neuroimmunology.

Conclusion: Nevertheless, from the pathophysiological perspective AD is significantly more than a loss of memory. In the initial stages of AD pathogenesis, variations in the dopaminergic pathway along with serotonin diminution play an important role. This may explain why depression is associated with the onset of AD. All these pathophysiological events take place together with immunomodulatory changes that trigger tau oligomerization in the course of neurofibrillary tangles formation. Interestingly, mood disorders appear to be followed by neuroinflammatory processes and structural/functional alterations that lead to cognitive impairment in the context of AD. PMID: 30069256 [PubMed]
Source: The Open Neurology Journal - Category: Neurology Tags: Open Neurol J Source Type: research

Related Links:

The barrier between mind and body appears to be crumbling. Clinical practice and public perception need to catch upUnlikely as it may seem, #inflammation has become a hashtag. It seems to be everywhere suddenly, up to all sorts of tricks. Rather than simply being on our side, fighting infections and healing wounds, it turns out to have a dark side as well: the role it plays in causing us harm.It ’s now clear that inflammation is part of the problem in many, if not all, diseases of the body. And targeting immune or inflammatory causes of disease has led to a series of breakthroughs, from new treatments for rheumatoid ...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Mental health Psychiatry Multiple sclerosis Depression Dementia Society Medical research Science UK news Alzheimer's Parkinson's disease Schizophrenia Source Type: news
(University of California - Riverside) New UC Riverside research shows soybean oil not only leads to obesity and diabetes, but could also affect neurological conditions like autism, Alzheimer's disease, anxiety, and depression.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
(Regenstrief Institute) In the first randomized controlled trial to evaluate pros and cons of population screening for dementia, Regenstrief Institute and Indiana University School of Medicine researchers found no harm, as measured by patient reported depressive and anxiety symptoms, from screening for Alzheimer's disease and related dementia in diverse rural, suburban and urban primary care clinics.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Authors: Cartz-Piver L, Polin C, Diebolt C, Chouly M, Garçonnot LA, Clément JP, Calvet B, Couratier P Abstract Therapeutic patient education (TPE) is the process by which health professionals impart information to help patients self-manage their chronic disease: it is an essential part of treatment of long-term diseases and conditions. Memory loss and other cognitive disorders are usually considered as obstacles to TPE for patients with Alzheimer's disease or related disorders (ADRD). Over 100 patients with different forms of ADRD and caregivers have benefited from TPE programs since 2011 at the Limog...
Source: Revue Neurologique - Category: Neurology Tags: Rev Neurol (Paris) Source Type: research
DISCUSSION: f-bvFTD and s-bvFTD cases are clinically similar, suggesting the generalizability of novel biomarkers, therapies, and clinical tools developed in either form to the other. PMID: 31914226 [PubMed - in process]
Source: The Journal of Alzheimers Association - Category: Psychiatry Tags: Alzheimers Dement Source Type: research
This study quantifies the influence of mutation awareness on clinical symptoms, cognition, and biomarkers. METHODS: Mutation carriers and non-carriers from the Dominantly Inherited Alzheimer Network (DIAN) were stratified based on knowledge of mutation status. Rates of change on standard clinical, cognitive, and neuroimaging outcomes were examined. RESULTS: Mutation knowledge had no associations with cognitive decline, clinical progression, amyloid deposition, hippocampal volume, or depression in either carriers or non-carriers. Carriers who learned their status mid-study had slightly higher levels of depression an...
Source: The Journal of Alzheimers Association - Category: Psychiatry Tags: Alzheimers Dement Source Type: research
Abstract The occurrence of major depressive disorder (MDD) has been linked to an increased vulnerability to stress. The basolateral amygdala (BLA) is one of the critical brain areas that involved in the regulation of pathological reactivity to stress. Increasing evidence indicates that the EphB2 receptor (EphB2) plays a critical role in neuropsychiatric disorders, such as Alzheimer's disease, pain and anxiety. However, whether the EphB2 in the BLA is involved in stress vulnerability is unclear. Here, we identified EphB2 in the BLA as a key regulator contributed to the modulation of stress vulnerability in adult mi...
Source: Neuropharmacology - Category: Drugs & Pharmacology Authors: Tags: Neuropharmacology Source Type: research
ConclusionsDepression may be an independent factor representing early neurodegeneration in elder patients with MCI. Further studies are warranted to assess whether effective management of NPS promotes the cognitive functions.
Source: The Journal of Nutrition, Health and Aging - Category: Nutrition Source Type: research
CONCLUSION: Pro and prebiotics can improve mental health and psychological function and can be offered as new medicines for common mental disorders however more clinical studies are necessary to conduct regarding the clinical significance of the effects and their bioequivalence or superiority against current treatments. PMID: 31914909 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Biotechnology - Category: Biotechnology Authors: Tags: Curr Pharm Biotechnol Source Type: research
Conclusion A great deal of progress is being made in the matter of treating aging: in advocacy, in funding, in the research and development. It can never be enough, and it can never be fast enough, given the enormous cost in suffering and lost lives. The longevity industry is really only just getting started in the grand scheme of things: it looks vast to those of us who followed the slow, halting progress in aging research that was the state of things a decade or two ago. But it is still tiny compared to the rest of the medical industry, and it remains the case that there is a great deal of work yet to be done at all...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
More News: Alzheimer's | Brain | Depression | Neurology